Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway

George P. Kim, Axel F Grothey

Research output: Contribution to journalArticle

Abstract

In the past several years, significant advances in the treatment of colorectal cancer (CRC) have been made. With the introduction of irinotecan and oxaliplatin combined with infusional 5-fluororuracil, survival times for patients with metastatic CRC have nearly doubled. With the incorporation of biologic agents that target the vascular endothelial growth factor and epidermal growth factor (EGF) pathways, additional improvements in response, progression-free survival, and overall survival have been seen in patients with advanced, metastatic disease. This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin- containing regimens.

Original languageEnglish (US)
JournalClinical Colorectal Cancer
Volume5
Issue numberSUPPL. 2
DOIs
StatePublished - 2005

Fingerprint

oxaliplatin
Epidermal Growth Factor Receptor
Colorectal Neoplasms
irinotecan
Survival
Biological Factors
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Disease-Free Survival

Keywords

  • 5-fluorouracil
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • Chemotherapy
  • Irinotecan

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. / Kim, George P.; Grothey, Axel F.

In: Clinical Colorectal Cancer, Vol. 5, No. SUPPL. 2, 2005.

Research output: Contribution to journalArticle

@article{c9bfc34c73174504af6bcf1834adc9d1,
title = "Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway",
abstract = "In the past several years, significant advances in the treatment of colorectal cancer (CRC) have been made. With the introduction of irinotecan and oxaliplatin combined with infusional 5-fluororuracil, survival times for patients with metastatic CRC have nearly doubled. With the incorporation of biologic agents that target the vascular endothelial growth factor and epidermal growth factor (EGF) pathways, additional improvements in response, progression-free survival, and overall survival have been seen in patients with advanced, metastatic disease. This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin- containing regimens.",
keywords = "5-fluorouracil, Bevacizumab, Capecitabine, Cetuximab, Chemotherapy, Irinotecan",
author = "Kim, {George P.} and Grothey, {Axel F}",
year = "2005",
doi = "10.3816/CCC.2005.s.012",
language = "English (US)",
volume = "5",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway

AU - Kim, George P.

AU - Grothey, Axel F

PY - 2005

Y1 - 2005

N2 - In the past several years, significant advances in the treatment of colorectal cancer (CRC) have been made. With the introduction of irinotecan and oxaliplatin combined with infusional 5-fluororuracil, survival times for patients with metastatic CRC have nearly doubled. With the incorporation of biologic agents that target the vascular endothelial growth factor and epidermal growth factor (EGF) pathways, additional improvements in response, progression-free survival, and overall survival have been seen in patients with advanced, metastatic disease. This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin- containing regimens.

AB - In the past several years, significant advances in the treatment of colorectal cancer (CRC) have been made. With the introduction of irinotecan and oxaliplatin combined with infusional 5-fluororuracil, survival times for patients with metastatic CRC have nearly doubled. With the incorporation of biologic agents that target the vascular endothelial growth factor and epidermal growth factor (EGF) pathways, additional improvements in response, progression-free survival, and overall survival have been seen in patients with advanced, metastatic disease. This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin- containing regimens.

KW - 5-fluorouracil

KW - Bevacizumab

KW - Capecitabine

KW - Cetuximab

KW - Chemotherapy

KW - Irinotecan

UR - http://www.scopus.com/inward/record.url?scp=33644664671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644664671&partnerID=8YFLogxK

U2 - 10.3816/CCC.2005.s.012

DO - 10.3816/CCC.2005.s.012

M3 - Article

C2 - 16336754

AN - SCOPUS:33644664671

VL - 5

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - SUPPL. 2

ER -